Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers

2 Sept 2016

Abstract excerpt

OBJECTIVE: The early natural history of sarcomere mutations and the evolution to hypertrophic cardiomyopathy (HCM) are poorly characterised. To describe phenotypic progression, we compared mutation carriers who developed HCM to those who did not during prospective longitudinal investigation. METHODS: Sarcomere mutation carriers without baseline left ventricular hypertrophy (LVH) were studied during participation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac Fibrosis and Remodeling
Share to Cardiomyopathy and Myosin Studies
Share to Cardiovascular Function and Risk Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27590665
DOI: 10.1136/heartjnl-2016-310015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriersPMID 27590665Read ↗

Hypertrophic cardiomyopathy: preclinical and early phenotype.Semantic proximity Read ↗

[Clinical spectrum of preclinical hypertrophic cardiomyopathy: characterizing carriers of sarcomere gene mutation].Semantic proximity Read ↗

Phenotypic Spectrum of Subclinical Sarcomere-Related Hypertrophic Cardiomyopathy and Transition to Overt Disease.Semantic proximity Read ↗

Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.Semantic proximity Read ↗

Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.Semantic proximity Read ↗

The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.Semantic proximity Read ↗

The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.Semantic proximity Read ↗

Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.Semantic proximity Read ↗

Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.Semantic proximity Read ↗

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry.Semantic proximity Read ↗

Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations.Semantic proximity Read ↗

Clinical Features and Prospective Outcomes of Thin Filament Hypertrophic Cardiomyopathy: Intrinsic Data and Comparative Insights from Other CohortsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.